Brain MRI atrophy quantification in MS

Maria A. Rocca, Marco Battaglini, Ralph H.B. Benedict, Nicola De Stefano, Jeroen J.G. Geurts, Roland G. Henry, Mark A. Horsfield, Mark Jenkinson, Elisabetta Pagani, Massimo Filippi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain atrophy in MS, this review attempts to guide the clinician towards a better understanding of the methods currently used for quantifying brain atrophy in this condition. Important physiologic factors that affect brain volume measures are also considered. Finally, the most recent research on brain atrophy in MS is summarized, including whole brain and various compartments thereof (i.e., white matter, gray matter, selected CNS structures). Current methods provide sufficient precision for cohort studies, but are not adequate for confidently assessing changes in individual patients over the scale of months or a few years.

LanguageEnglish
Pages403-413
Number of pages11
JournalNeurology
Volume88
Issue number4
DOIs
Publication statusPublished - 24 Jan 2017
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Rocca, M. A., Battaglini, M., Benedict, R. H. B., De Stefano, N., Geurts, J. J. G., Henry, R. G., ... Filippi, M. (2017). Brain MRI atrophy quantification in MS. Neurology, 88(4), 403-413. https://doi.org/10.1212/WNL.0000000000003542
Rocca, Maria A. ; Battaglini, Marco ; Benedict, Ralph H.B. ; De Stefano, Nicola ; Geurts, Jeroen J.G. ; Henry, Roland G. ; Horsfield, Mark A. ; Jenkinson, Mark ; Pagani, Elisabetta ; Filippi, Massimo. / Brain MRI atrophy quantification in MS. In: Neurology. 2017 ; Vol. 88, No. 4. pp. 403-413.
@article{ce7c64b872f1490eaa770c31f4431f15,
title = "Brain MRI atrophy quantification in MS",
abstract = "Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain atrophy in MS, this review attempts to guide the clinician towards a better understanding of the methods currently used for quantifying brain atrophy in this condition. Important physiologic factors that affect brain volume measures are also considered. Finally, the most recent research on brain atrophy in MS is summarized, including whole brain and various compartments thereof (i.e., white matter, gray matter, selected CNS structures). Current methods provide sufficient precision for cohort studies, but are not adequate for confidently assessing changes in individual patients over the scale of months or a few years.",
author = "Rocca, {Maria A.} and Marco Battaglini and Benedict, {Ralph H.B.} and {De Stefano}, Nicola and Geurts, {Jeroen J.G.} and Henry, {Roland G.} and Horsfield, {Mark A.} and Mark Jenkinson and Elisabetta Pagani and Massimo Filippi",
year = "2017",
month = "1",
day = "24",
doi = "10.1212/WNL.0000000000003542",
language = "English",
volume = "88",
pages = "403--413",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Rocca, MA, Battaglini, M, Benedict, RHB, De Stefano, N, Geurts, JJG, Henry, RG, Horsfield, MA, Jenkinson, M, Pagani, E & Filippi, M 2017, 'Brain MRI atrophy quantification in MS', Neurology, vol. 88, no. 4, pp. 403-413. https://doi.org/10.1212/WNL.0000000000003542

Brain MRI atrophy quantification in MS. / Rocca, Maria A.; Battaglini, Marco; Benedict, Ralph H.B.; De Stefano, Nicola; Geurts, Jeroen J.G.; Henry, Roland G.; Horsfield, Mark A.; Jenkinson, Mark; Pagani, Elisabetta; Filippi, Massimo.

In: Neurology, Vol. 88, No. 4, 24.01.2017, p. 403-413.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brain MRI atrophy quantification in MS

AU - Rocca, Maria A.

AU - Battaglini, Marco

AU - Benedict, Ralph H.B.

AU - De Stefano, Nicola

AU - Geurts, Jeroen J.G.

AU - Henry, Roland G.

AU - Horsfield, Mark A.

AU - Jenkinson, Mark

AU - Pagani, Elisabetta

AU - Filippi, Massimo

PY - 2017/1/24

Y1 - 2017/1/24

N2 - Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain atrophy in MS, this review attempts to guide the clinician towards a better understanding of the methods currently used for quantifying brain atrophy in this condition. Important physiologic factors that affect brain volume measures are also considered. Finally, the most recent research on brain atrophy in MS is summarized, including whole brain and various compartments thereof (i.e., white matter, gray matter, selected CNS structures). Current methods provide sufficient precision for cohort studies, but are not adequate for confidently assessing changes in individual patients over the scale of months or a few years.

AB - Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain atrophy in MS, this review attempts to guide the clinician towards a better understanding of the methods currently used for quantifying brain atrophy in this condition. Important physiologic factors that affect brain volume measures are also considered. Finally, the most recent research on brain atrophy in MS is summarized, including whole brain and various compartments thereof (i.e., white matter, gray matter, selected CNS structures). Current methods provide sufficient precision for cohort studies, but are not adequate for confidently assessing changes in individual patients over the scale of months or a few years.

UR - http://www.scopus.com/inward/record.url?scp=85010875136&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003542

DO - 10.1212/WNL.0000000000003542

M3 - Article

VL - 88

SP - 403

EP - 413

JO - Neurology

T2 - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -

Rocca MA, Battaglini M, Benedict RHB, De Stefano N, Geurts JJG, Henry RG et al. Brain MRI atrophy quantification in MS. Neurology. 2017 Jan 24;88(4):403-413. https://doi.org/10.1212/WNL.0000000000003542